U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of the Chief Scientist
  6. National Center for Toxicological Research
  7. Science & Research (NCTR)
  8. Igor Pogribny
  1. National Center for Toxicological Research

Igor Pogribny M.D.

Igor Pogribny

 

Research Biologist — Division of Biochemical Toxicology

Igor Pogribny
Igor Pogribny, M.D., Ph.D.

(870) 543-7391
NCTRResearch@fda.hhs.gov  

Back to NCTR Principal Investigators page


 About  |  Publications  |  Lab Members


Background

Dr. Igor Pogribny received an M.D. in 1982 and a Ph.D. in biochemistry and oncology in 1986 in the Ukraine and joined NCTR in 1999. He is the recipient of the FDA “Outstanding Service Award” (2006) and FDA “Commissioner’s Special Citation Award” (2011).

Research Interests

Dr. Pogribny’s research interests and experience are centered in three major areas: 1) to elucidate the role and significance of genetic and epigenetic alterations in the development and progression of cancer, 2) to investigate and establish the role of epigenetic alterations as indicators of exposure to genotoxic and non-genotoxic carcinogens ─ critical for the primary prevention of neoplasia in humans, and 3) to conduct research on nonalcoholic fatty liver disease (NAFLD).

NAFLD is strongly associated with metabolic syndrome and obesity. It includes a range of liver injury from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis, and is a major health problem and leading cause of chronic liver disease in the United States and Western countries. Dr. Pogribny’s laboratory aims to better understand the role of individual genetic and genomic ─ including epigenomic ─ susceptibility factors in the development of NAFLD.  Identification of these susceptibility factors may facilitate the development of diagnostic tools that can be used to identify high-risk individuals to help prevent NAFLD-related liver cancer.

Professional Societies/National and International Groups

American Association for Cancer Research
Member
2012 – Present

Society of Toxicology
Member
2012 – Present

BACK TO TOP

Selected Publications

Furan-Induced Transcriptomic and Gene-Specific DNA Methylation Changes in the Livers Of Fischer 344 Rats in a 2-Year Carcinogenicity Study.
Tryndyak V, de Conti A, Doerge D, Olson GR, Beland FA, Pogribny IP.
Arch Toxicol. 2016 Jul 7; [in press]
 
Irreversible Down-Regulation of mir-375 in the Livers of Fischer 344 Rats after Chronic Furan Exposure.
de Conti A, Tryndyak V, Doerge DR, Beland FA, Pogribny IP. 
Food Chem Toxicol. 2016 Jun 28; pii: S0278-6915(16)30207-1.

Differentially Expressed MicroRNAs Provide Mechanistic Insight into Fibrosis-Associated Liver Carcinogenesis in Mice.
Marrone AK, Shpyleva S, Chappell G, Tryndyak V, Uehara T, Tsuchiya M, Beland FA, Rusyn I, Pogribny IP.
Mol Carcinog. 2016 May; 55(5):808-17.

Epigenetic Alterations Induced by Genotoxic Occupational and Environmental Human Chemical Carcinogens: A Systematic Literature Review.
Chappell G, Pogribny IP, Guyton KZ, Rusyn I.
Mutat Res Rev Mutat Res. 2016 Apr-Jun; 768:27-45.

Status of Hepatic DNA Methylome Predetermines and Modulates the Severity of Non-Alcoholic Fatty Liver Injury in Mice.
Tryndyak VP, Han T, Fuscoe JC, Ross SA, Beland FA, Pogribny IP.
BMC Genomics. 2016 Apr 22; 17:298.

MicroRNA Changes, Activation of Progenitor Cells, and Severity of Liver Injury in Mice Induced by Choline and Folate Deficiency.
Tryndyak VP, Marrone AK, Latendresse JR, Muskhelishvili L, Beland FA, Pogribny IP.
J Nutr Biochem. 2016 Feb; 28:83-90.

MicroRNA Responses to the Genotoxic Carcinogens Aflatoxin B1 and Benzo[A]Pyrene In Human HepaRG Cells.
Marrone AK, Tryndyak V, Beland FA, Pogribny IP. 
Toxicol Sci. 2016 Feb; 149(2):496-502.

The Role of MicroRNAs in the Development and Progression of Chemical-Associated Cancers.
Pogribny IP, Beland FA, Rusyn I.
Toxicol Appl Pharmacol. 2015 Nov 24; pii: S0041-008X(15)30140-X.

Persistence of Furan-Induced Epigenetic Aberrations in the Livers of F344 Rats.
de Conti A, Kobets T, Tryndyak V, Burnett SD, Han T, Fuscoe JC, Beland FA, Doerge DR, Pogribny IP. 
Toxicol Sci. 2015 Apr; 144(2):217-26.

Genetic and Epigenetic Changes in Fibrosis-Associated Hepatocarcinogenesis in Mice.
Chappell G, Kutanzi K, Uehara T, Tryndyak V, Hong H-H, Hoenerhoff M, Beland FA, Rusyn I, Pogribny IP.
Int J Cancer. 2014 Jun 15; 134(12):2778-88.

BACK TO TOP

Lab Members

Contact Information for all lab members:
(870) 543-7391
NCTRResearch@fda.hhs.gov

Aline de Conti, Ph.D.
Staff Fellow

Mekonnen Lemma Dechassa, Ph.D.
Commissioner Fellow

Kostiantyn Dreval, Ph.D.
ORISE Postdoctoral Fellow

Volodymyr Tryndyak, Ph.D
Senior Staff Fellow

BACK TO TOP
 


Contact Information
Igor Pogribny
(870) 543-7391
Expertise
Approach